| 1. |
- Abbafati, Cristiana, et al.
(författare)
-
- 2020
-
Tidskriftsartikel (refereegranskat)
|
|
| 2. |
- Bahrami, Behdokht, et al.
(författare)
-
Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy
- 2015
-
Ingår i: Tumor Biology. - Stockholm : Karolinska Institutet, Dept of Oncology-Pathology. - 1423-0380 .- 1010-4283.
-
Tidskriftsartikel (refereegranskat)abstract
- The selective and efficient drug delivery to tumor cells can remarkably improve different cancer therapeutic approaches. There are several nanoparticles (NPs) which can act as a potent drug carrier for cancer therapy. However, the specific drug delivery to cancer cells is an important issue which should be considered before designing new NPs for in vivo application. It has been shown that cancer cells over-express folate receptor (FR) in order to improve their growth. As normal cells express a significantly lower levels of FR compared to tumor cells, it seems that folate molecules can be used as potent targeting moieties in different nanocarrier-based therapeutic approaches. Moreover, there is evidence which implies folate-conjugated NPs can selectively deliver anti-tumor drugs into cancer cells both in vitro and in vivo. In this review, we will discuss about the efficiency of different folate-conjugated NPs in cancer therapy.
|
|
| 3. |
- Kokhaei, Parviz, et al.
(författare)
-
Ibrutinib-A double-edge sword in cancer and autoimmune disorders
- 2015
-
Ingår i: Journal of Drug Targeting. - Stockholm : Karolinska Institutet, Dept of Oncology-Pathology. - 1061-186X. ; 24:5, s. 373-385
-
Tidskriftsartikel (refereegranskat)abstract
- Targeted therapies have appeared as new treatment options for several disease types, including cancer and autoimmune disorders. Of several targets, tyrosine kinases (TKs) are among the most promising. Overexpression of TKs provides a target for novel therapeutic agents, including small molecule inhibitors of tyrosine kinases (TKI). Ibrutinib (PCI-32765) is a TKI of Bruton’s tyrosine kinase (Btk), a key kinase of the B-cell receptor signaling pathway that plays a significant role in the proliferation, differentiation and survival of B cells. In addition to inhibitory effects, recent studies have shown that ibrutinib has multiple immunomodulatory effects. It binds covalently to IL-2 inducible tyrosine kinase (Itk) in T lymphocytes and suppresses the survival of T-helper (Th) 2 cells. This changes the balance of Th1/Th2 cells toward Th1 subset, which are the main immune cells targeting tumor cells. The dual activity of ibrutinib has paid a great attention and several studies are evaluating the anti-tumor and immunomodulatory effects in cancer, autoimmune disorders and infectious diseases. In this article we review the inhibitory and immunomodulatory effects of ibrutinib in B-cell malignancies, autoimmune diseases and infections, as well as the communication between the Ror1 receptor tyrosine kinase and BCR and effects of ibrutinib on this crosstalk.
|
|
| 4. |
- Yousefi, Mehdi, et al.
(författare)
-
The skewed balance between regulatory T cells and Th17 in chronic lymphocytic leukemia
- 2015
-
Ingår i: Future Oncology. - Stockholm : Karolinska Institutet, Dept of Oncology-Pathology. - 1479-6694 .- 1744-8301.
-
Tidskriftsartikel (refereegranskat)abstract
- While Tregs maintain self-tolerance and inhibit antitumor responses, T helper (Th)17 cells may enhance inflammatory and antitumor responses. The balance between these two important T-cell subsets has been skewed in many immunopathologic conditions such as autoimmune and cancer diseases. B-cell chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the western world and is characterized with monoclonal expansion of B lymphocytes. There is evidence which implies that the progression of CLL is associated with expansion of Treg and downregulation of Th17 cells. In this review, we will discuss about immunobiology of Treg and Th17 cells and their role in immunopathogenesis of CLL as well as their reciprocal changes during disease progression.
|
|
